One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
Crosscope and KFBIO join forces to lead digital transformation for pathology in India and emerging markets
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The medicine is now approved for eight indications across five different types of cancer in China.
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
TCS provides clinical research services such as clinical data management, regulatory affairs, pharmacovigilance, risk-based monitoring, biostatistics and programming, medical writing, medical affairs and medico marketing, and health economics and outcomes research
Subscribe To Our Newsletter & Stay Updated
